Summary

The 7 major treatment resistant depression markets reached a value of US$ 3,295.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6,286.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.05% during 2024-2034.

The treatment resistant depression market has been comprehensively analyzed in IMARC's new report titled "Treatment Resistant Depression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Treatment resistant depression refers to a type of depression that does not respond to at least two types of antidepressant medications. This condition results when the treatment drugs are ineffective in alleviating the symptoms of depression. People suffering from the illness may experience persistent feelings of sadness, hopelessness, and worthlessness, as well as other symptoms such as fatigue, changes in appetite and sleep patterns, difficulty concentrating, and a loss of interest in activities. The other common indications of the ailment include low energy and motivation, irritability, confusion, poor sexual drive, suicide ideation, etc. The diagnosis of treatment resistant depression mainly relies on a combination of the patient’s medical and psychiatric history, clinical features, and physical tests. The patient health questionnaire (PHQ) to measure and screen depressive symptoms is further utilized for disease diagnosis by healthcare professionals.

The rising cases of psychological issues, such as low motivation, poor adherence to treatment, high levels of stress, changes in brain chemistry, etc., are primarily driving the treatment resistant depression market. In addition to this, the increasing incidences of genetic and biological defects that result in delayed or no response to antidepressant drugs or other treatments are also propelling the market growth. Furthermore, the widespread adoption of augmentation therapy with synthetic thyroid hormone and mood-stabilizing drugs, which can improve recovery in patients, is creating a positive outlook for the market. Besides this, the emerging popularity of a non-invasive transcranial magnetic stimulation technique, since it utilizes electromagnetic pulses to regulate the neural function of brain structures associated with this condition, is also bolstering the market growth. Additionally, the inflating demand for cognitive behavioral therapy to potentially improve interpersonal skills by changing and identifying unhealthy thought patterns or emotions is acting as another significant growth-inducing factor. Moreover, the escalating application of esketamine nasal spray for disease treatment, owing to its numerous advantages including activation of neuroplasticity, enhancement of the brain’s ability to positively alter and grow, and improved outcomes in patients, is expected to drive the treatment resistant depression market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the treatment resistant depression market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for treatment resistant depression and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the treatment resistant depression market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the treatment resistant depression market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the treatment resistant depression market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current treatment resistant depression marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the treatment resistant depression market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the treatment resistant depression market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the treatment resistant depression market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of treatment resistant depression across the seven major markets?
What is the number of prevalent cases (2018-2034) of treatment resistant depression by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of treatment resistant depression by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with treatment resistant depression across the seven major markets?
What is the size of the treatment resistant depression patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of treatment resistant depression?
What will be the growth rate of patients across the seven major markets?

Treatment Resistant Depression: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for treatment resistant depression drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the treatment resistant depression market?
What are the key regulatory events related to the treatment resistant depression market?
What is the structure of clinical trial landscape by status related to the treatment resistant depression market?
What is the structure of clinical trial landscape by phase related to the treatment resistant depression market?
What is the structure of clinical trial landscape by route of administration related to the treatment resistant depression market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Treatment Resistant Depression - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Treatment Resistant Depression - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Treatment Resistant Depression - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Treatment Resistant Depression - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Treatment Resistant Depression - Unmet Needs

10 Treatment Resistant Depression - Key Endpoints of Treatment

11 Treatment Resistant Depression - Marketed Products
11.1 List of Treatment Resistant Depression Marketed Drugs Across the Top 7 Markets
11.1.1 Spravato (Esketamine) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Treatment Resistant Depression - Pipeline Drugs
12.1 List of Treatment Resistant Depression Pipeline Drugs Across the Top 7 Markets
12.1.1 MIJ821 - Novartis
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MK 1942 - Merck Sharp & Dohme Corp
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Psilocybin - COMPASS Pathways
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GH 001 - GH Research
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BPL-003 - Beckley Psytech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Treatment Resistant Depression - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Treatment Resistant Depression – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Treatment Resistant Depression - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Treatment Resistant Depression - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Treatment Resistant Depression - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Treatment Resistant Depression - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Treatment Resistant Depression - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Treatment Resistant Depression - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Treatment Resistant Depression - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Treatment Resistant Depression - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Treatment Resistant Depression - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Treatment Resistant Depression - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Treatment Resistant Depression - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Treatment Resistant Depression - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Treatment Resistant Depression - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Treatment Resistant Depression - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Treatment Resistant Depression - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Treatment Resistant Depression - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Treatment Resistant Depression - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Treatment Resistant Depression - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Treatment Resistant Depression - Access and Reimbursement Overview

16 Treatment Resistant Depression - Recent Events and Inputs From Key Opinion Leaders

17 Treatment Resistant Depression Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Treatment Resistant Depression Market – Strategic Recommendations

19 Appendix